Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Polycystic Ovary Syndrome | 57 | 2022 | 202 | 10.690 |
Why?
|
Insulin Resistance | 32 | 2022 | 377 | 3.850 |
Why?
|
Hyperandrogenism | 14 | 2022 | 42 | 3.100 |
Why?
|
Sleep Apnea, Obstructive | 10 | 2022 | 217 | 2.820 |
Why?
|
Diabetes Mellitus, Type 2 | 32 | 2022 | 1372 | 2.790 |
Why?
|
Glucose Intolerance | 18 | 2022 | 96 | 2.350 |
Why?
|
Insulin | 32 | 2022 | 1159 | 1.760 |
Why?
|
Blood Glucose | 28 | 2022 | 873 | 1.760 |
Why?
|
Metformin | 14 | 2022 | 128 | 1.750 |
Why?
|
Androgens | 15 | 2018 | 164 | 1.650 |
Why?
|
Hypoglycemic Agents | 19 | 2022 | 377 | 1.510 |
Why?
|
Testosterone | 17 | 2015 | 268 | 1.300 |
Why?
|
Ovary | 9 | 2016 | 250 | 1.160 |
Why?
|
Glucose Tolerance Test | 23 | 2021 | 228 | 1.000 |
Why?
|
Female | 89 | 2022 | 44405 | 0.820 |
Why?
|
Ovarian Diseases | 6 | 2015 | 32 | 0.790 |
Why?
|
Metabolic Diseases | 2 | 2011 | 48 | 0.770 |
Why?
|
Thiazolidinediones | 10 | 2007 | 82 | 0.770 |
Why?
|
Hirsutism | 10 | 2018 | 61 | 0.690 |
Why?
|
Non-alcoholic Fatty Liver Disease | 1 | 2022 | 210 | 0.670 |
Why?
|
Humans | 106 | 2022 | 86281 | 0.640 |
Why?
|
Adult | 60 | 2022 | 25577 | 0.630 |
Why?
|
Polymorphism, Genetic | 6 | 2005 | 819 | 0.610 |
Why?
|
Dexamethasone | 10 | 2011 | 326 | 0.600 |
Why?
|
Phosphoproteins | 3 | 2009 | 253 | 0.580 |
Why?
|
Gonadotropin-Releasing Hormone | 9 | 2010 | 103 | 0.570 |
Why?
|
Prediabetic State | 3 | 2021 | 39 | 0.560 |
Why?
|
Sleep | 4 | 2019 | 440 | 0.560 |
Why?
|
Chromans | 8 | 2005 | 30 | 0.540 |
Why?
|
Hyperinsulinism | 5 | 2016 | 51 | 0.520 |
Why?
|
Adrenocorticotropic Hormone | 6 | 2011 | 131 | 0.510 |
Why?
|
Body Mass Index | 11 | 2013 | 770 | 0.510 |
Why?
|
Obesity | 6 | 2019 | 962 | 0.470 |
Why?
|
Depression | 2 | 2015 | 472 | 0.430 |
Why?
|
Islets of Langerhans | 6 | 2004 | 544 | 0.430 |
Why?
|
Anti-Mullerian Hormone | 1 | 2012 | 10 | 0.430 |
Why?
|
Glucose | 7 | 2021 | 637 | 0.420 |
Why?
|
Gastroplasty | 2 | 2022 | 21 | 0.410 |
Why?
|
Cardiovascular Diseases | 4 | 2021 | 826 | 0.410 |
Why?
|
Metabolism | 1 | 2010 | 24 | 0.390 |
Why?
|
Lipids | 3 | 2009 | 269 | 0.380 |
Why?
|
Sleep Wake Disorders | 3 | 2019 | 115 | 0.380 |
Why?
|
Nafarelin | 10 | 1996 | 43 | 0.360 |
Why?
|
Hyperglycemia | 2 | 2017 | 176 | 0.350 |
Why?
|
Adolescent | 26 | 2021 | 8968 | 0.350 |
Why?
|
Diabetes Mellitus | 6 | 2018 | 801 | 0.330 |
Why?
|
Leuprolide | 4 | 2010 | 30 | 0.320 |
Why?
|
Thiazoles | 5 | 2003 | 131 | 0.320 |
Why?
|
Insulin-Secreting Cells | 3 | 2019 | 397 | 0.320 |
Why?
|
Exercise Therapy | 2 | 2019 | 78 | 0.320 |
Why?
|
Androgen Antagonists | 4 | 2018 | 140 | 0.300 |
Why?
|
Metabolic Syndrome | 2 | 2005 | 141 | 0.290 |
Why?
|
Gonadotropins | 5 | 2010 | 34 | 0.270 |
Why?
|
Young Adult | 14 | 2021 | 5961 | 0.270 |
Why?
|
Polysomnography | 4 | 2012 | 150 | 0.260 |
Why?
|
Genetic Variation | 3 | 2017 | 1349 | 0.260 |
Why?
|
Respiratory Mechanics | 1 | 2005 | 102 | 0.260 |
Why?
|
Case-Control Studies | 7 | 2018 | 1801 | 0.250 |
Why?
|
Phosphoprotein Phosphatases | 1 | 2004 | 57 | 0.250 |
Why?
|
Genetic Predisposition to Disease | 6 | 2018 | 2267 | 0.250 |
Why?
|
Evidence-Based Medicine | 4 | 2018 | 429 | 0.240 |
Why?
|
Mood Disorders | 1 | 2004 | 81 | 0.240 |
Why?
|
Coronary Artery Disease | 2 | 2018 | 347 | 0.230 |
Why?
|
Cohort Studies | 6 | 2019 | 2759 | 0.220 |
Why?
|
Diabetes, Gestational | 2 | 2013 | 39 | 0.210 |
Why?
|
Calpain | 1 | 2002 | 111 | 0.200 |
Why?
|
Genome-Wide Association Study | 4 | 2018 | 1611 | 0.200 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2002 | 122 | 0.200 |
Why?
|
Phenotype | 8 | 2018 | 2375 | 0.200 |
Why?
|
Male | 25 | 2022 | 40860 | 0.190 |
Why?
|
Menstruation Disturbances | 2 | 2018 | 24 | 0.190 |
Why?
|
17-alpha-Hydroxyprogesterone | 5 | 2011 | 30 | 0.190 |
Why?
|
Sleep Deprivation | 2 | 2012 | 137 | 0.190 |
Why?
|
Hydroxyprogesterones | 4 | 1994 | 21 | 0.190 |
Why?
|
Follow-Up Studies | 5 | 2020 | 3616 | 0.190 |
Why?
|
Contraceptives, Oral | 2 | 2013 | 46 | 0.180 |
Why?
|
Steroids | 3 | 2009 | 172 | 0.180 |
Why?
|
Hypogonadism | 2 | 2010 | 37 | 0.180 |
Why?
|
Pituitary Gland | 2 | 1989 | 117 | 0.180 |
Why?
|
Luteinizing Hormone | 9 | 2009 | 167 | 0.170 |
Why?
|
Oligomenorrhea | 4 | 2007 | 11 | 0.170 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2019 | 48 | 0.170 |
Why?
|
Risk Reduction Behavior | 2 | 2017 | 98 | 0.170 |
Why?
|
Hair Removal | 1 | 2018 | 14 | 0.160 |
Why?
|
Thyroid Diseases | 2 | 1989 | 104 | 0.160 |
Why?
|
Time Factors | 8 | 2019 | 5198 | 0.160 |
Why?
|
Thyrotropin | 2 | 1989 | 280 | 0.160 |
Why?
|
Middle Aged | 15 | 2021 | 24957 | 0.160 |
Why?
|
Hepatocyte Nuclear Factor 4 | 1 | 2017 | 30 | 0.160 |
Why?
|
Follicle Stimulating Hormone | 7 | 2009 | 147 | 0.160 |
Why?
|
Biomarkers | 3 | 2017 | 1709 | 0.150 |
Why?
|
Weight Reduction Programs | 1 | 2017 | 13 | 0.150 |
Why?
|
Vascular Calcification | 1 | 2018 | 39 | 0.150 |
Why?
|
Fibrinolysis | 1 | 1997 | 35 | 0.150 |
Why?
|
Glucocorticoids | 4 | 2004 | 347 | 0.150 |
Why?
|
Acne Vulgaris | 3 | 2005 | 32 | 0.150 |
Why?
|
Body Composition | 1 | 2017 | 68 | 0.150 |
Why?
|
C-Peptide | 4 | 2019 | 174 | 0.150 |
Why?
|
Self-Management | 1 | 2017 | 29 | 0.150 |
Why?
|
Fasting | 3 | 2020 | 161 | 0.150 |
Why?
|
Psychiatric Status Rating Scales | 2 | 2015 | 486 | 0.150 |
Why?
|
Adrenal Glands | 3 | 2011 | 76 | 0.150 |
Why?
|
Glucose Clamp Technique | 4 | 2019 | 39 | 0.140 |
Why?
|
Hypoglycemia | 1 | 2017 | 106 | 0.140 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 1997 | 150 | 0.140 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2017 | 165 | 0.140 |
Why?
|
Reproduction | 1 | 2017 | 195 | 0.140 |
Why?
|
Exercise | 1 | 2019 | 315 | 0.140 |
Why?
|
Incidence | 3 | 2017 | 1568 | 0.140 |
Why?
|
Amenorrhea | 2 | 2007 | 27 | 0.130 |
Why?
|
Risk Factors | 8 | 2018 | 5397 | 0.130 |
Why?
|
Surveys and Questionnaires | 5 | 2019 | 2495 | 0.130 |
Why?
|
Regression Analysis | 2 | 2011 | 595 | 0.130 |
Why?
|
Hormones | 2 | 2010 | 140 | 0.130 |
Why?
|
Adrenal Hyperplasia, Congenital | 2 | 1992 | 25 | 0.120 |
Why?
|
Transcription Factors | 1 | 2002 | 1555 | 0.120 |
Why?
|
Models, Biological | 2 | 2017 | 1748 | 0.120 |
Why?
|
Patient Compliance | 2 | 2017 | 226 | 0.120 |
Why?
|
Prospective Studies | 4 | 2011 | 4194 | 0.120 |
Why?
|
Patient Education as Topic | 1 | 2017 | 351 | 0.120 |
Why?
|
Research Design | 1 | 2017 | 594 | 0.120 |
Why?
|
Insulin Receptor Substrate Proteins | 2 | 2004 | 55 | 0.120 |
Why?
|
Area Under Curve | 2 | 2005 | 334 | 0.110 |
Why?
|
Osmolar Concentration | 2 | 2012 | 181 | 0.110 |
Why?
|
Death Domain Receptor Signaling Adaptor Proteins | 1 | 2012 | 6 | 0.110 |
Why?
|
Diagnosis, Differential | 5 | 2005 | 1562 | 0.110 |
Why?
|
Hyperlipidemias | 2 | 2003 | 95 | 0.110 |
Why?
|
Stress, Psychological | 1 | 2015 | 313 | 0.110 |
Why?
|
Body Fat Distribution | 1 | 2011 | 13 | 0.100 |
Why?
|
Longitudinal Studies | 1 | 2015 | 1015 | 0.100 |
Why?
|
Dehydroepiandrosterone Sulfate | 3 | 2009 | 16 | 0.100 |
Why?
|
Ovarian Function Tests | 2 | 2000 | 8 | 0.100 |
Why?
|
Dose-Response Relationship, Drug | 7 | 2017 | 1958 | 0.100 |
Why?
|
Sex Characteristics | 3 | 2011 | 319 | 0.100 |
Why?
|
Self Report | 3 | 2019 | 287 | 0.100 |
Why?
|
Adipocytes | 1 | 2012 | 155 | 0.100 |
Why?
|
Organ Size | 1 | 2012 | 363 | 0.100 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2004 | 378 | 0.100 |
Why?
|
Age Factors | 2 | 2013 | 1842 | 0.100 |
Why?
|
Sleep Disorders, Circadian Rhythm | 1 | 2010 | 13 | 0.100 |
Why?
|
Animals | 7 | 2016 | 26518 | 0.100 |
Why?
|
Disease Progression | 1 | 2015 | 1531 | 0.100 |
Why?
|
Genotype | 4 | 2005 | 1850 | 0.100 |
Why?
|
Autonomic Nervous System | 1 | 2010 | 56 | 0.100 |
Why?
|
Ovarian Neoplasms | 1 | 1997 | 738 | 0.100 |
Why?
|
Pituitary-Adrenal System | 1 | 2010 | 64 | 0.090 |
Why?
|
Pregnancy Complications | 1 | 2013 | 336 | 0.090 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2010 | 81 | 0.090 |
Why?
|
Progesterone | 1 | 2010 | 107 | 0.090 |
Why?
|
Continuous Positive Airway Pressure | 1 | 2010 | 51 | 0.090 |
Why?
|
Cross-Sectional Studies | 3 | 2021 | 1610 | 0.090 |
Why?
|
Child | 7 | 2021 | 6913 | 0.090 |
Why?
|
Sympathetic Nervous System | 1 | 2010 | 104 | 0.090 |
Why?
|
Homeostasis | 2 | 2002 | 408 | 0.090 |
Why?
|
Perilipin-1 | 1 | 2009 | 7 | 0.090 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2015 | 566 | 0.090 |
Why?
|
Puberty, Delayed | 1 | 1989 | 19 | 0.090 |
Why?
|
Pregnancy Outcome | 1 | 2011 | 247 | 0.090 |
Why?
|
Pituitary Gland, Anterior | 1 | 1989 | 22 | 0.090 |
Why?
|
Testis | 1 | 1989 | 152 | 0.090 |
Why?
|
Estradiol | 4 | 2009 | 249 | 0.080 |
Why?
|
Stress, Physiological | 1 | 2010 | 226 | 0.080 |
Why?
|
Mutation, Missense | 2 | 2017 | 276 | 0.080 |
Why?
|
Aged | 5 | 2019 | 18353 | 0.080 |
Why?
|
Electrocardiography | 1 | 2010 | 478 | 0.080 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2009 | 122 | 0.080 |
Why?
|
Heart Rate | 1 | 2010 | 492 | 0.080 |
Why?
|
Life Style | 3 | 2021 | 188 | 0.080 |
Why?
|
Predictive Value of Tests | 3 | 2010 | 1671 | 0.080 |
Why?
|
Women's Health | 1 | 2009 | 100 | 0.080 |
Why?
|
Sleep Stages | 1 | 2008 | 45 | 0.080 |
Why?
|
Cholesterol, HDL | 2 | 2005 | 165 | 0.080 |
Why?
|
Arousal | 1 | 2008 | 170 | 0.080 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2007 | 18 | 0.080 |
Why?
|
Hemodynamics | 1 | 2010 | 710 | 0.080 |
Why?
|
Waist-Hip Ratio | 1 | 2005 | 18 | 0.070 |
Why?
|
17-Hydroxysteroid Dehydrogenases | 1 | 2005 | 11 | 0.070 |
Why?
|
Carrier Proteins | 1 | 2009 | 672 | 0.070 |
Why?
|
Diet, Reducing | 1 | 2005 | 31 | 0.070 |
Why?
|
AT Rich Sequence | 1 | 2004 | 7 | 0.060 |
Why?
|
Drug Therapy, Combination | 1 | 2007 | 893 | 0.060 |
Why?
|
Sleep Apnea Syndromes | 1 | 2005 | 102 | 0.060 |
Why?
|
Protein Phosphatase 1 | 1 | 2004 | 34 | 0.060 |
Why?
|
Alleles | 2 | 2012 | 1127 | 0.060 |
Why?
|
Matched-Pair Analysis | 1 | 2003 | 43 | 0.060 |
Why?
|
Mites | 1 | 2003 | 16 | 0.060 |
Why?
|
Premenopause | 2 | 2018 | 54 | 0.060 |
Why?
|
Personality Inventory | 1 | 2004 | 108 | 0.060 |
Why?
|
Body Image | 1 | 2004 | 76 | 0.060 |
Why?
|
Dust | 1 | 2003 | 26 | 0.060 |
Why?
|
Depressive Disorder | 1 | 2004 | 218 | 0.060 |
Why?
|
Infertility, Female | 1 | 2003 | 90 | 0.060 |
Why?
|
Administration, Oral | 2 | 2002 | 683 | 0.060 |
Why?
|
Allergens | 1 | 2003 | 179 | 0.060 |
Why?
|
Receptor, Insulin | 1 | 2002 | 54 | 0.050 |
Why?
|
Androstenedione | 2 | 1994 | 29 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2017 | 2350 | 0.050 |
Why?
|
Reference Values | 1 | 2003 | 673 | 0.050 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2004 | 689 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2018 | 1796 | 0.050 |
Why?
|
Diabetic Angiopathies | 1 | 2002 | 62 | 0.050 |
Why?
|
DNA Primers | 1 | 2002 | 542 | 0.050 |
Why?
|
3-Hydroxysteroid Dehydrogenases | 2 | 1993 | 22 | 0.050 |
Why?
|
Ovulation | 1 | 2001 | 67 | 0.050 |
Why?
|
Amino Acid Substitution | 1 | 2002 | 339 | 0.050 |
Why?
|
Quantitative Trait, Heritable | 1 | 2002 | 124 | 0.050 |
Why?
|
Ultrasonography | 3 | 2009 | 695 | 0.050 |
Why?
|
Heterozygote | 1 | 2002 | 365 | 0.050 |
Why?
|
Genetic Linkage | 2 | 1999 | 623 | 0.050 |
Why?
|
Mutation | 1 | 2012 | 3952 | 0.050 |
Why?
|
Weight Loss | 1 | 2022 | 229 | 0.050 |
Why?
|
Blood Pressure | 1 | 2005 | 1143 | 0.050 |
Why?
|
Receptors, LHRH | 1 | 1999 | 4 | 0.050 |
Why?
|
Haplotypes | 1 | 2002 | 642 | 0.050 |
Why?
|
Insulin-Like Growth Factor II | 1 | 1999 | 33 | 0.040 |
Why?
|
Jet Lag Syndrome | 1 | 2019 | 13 | 0.040 |
Why?
|
Thrombosis | 1 | 2002 | 296 | 0.040 |
Why?
|
Gene Expression Profiling | 1 | 2004 | 1381 | 0.040 |
Why?
|
Base Sequence | 1 | 2002 | 2329 | 0.040 |
Why?
|
Contraceptives, Oral, Combined | 1 | 2018 | 8 | 0.040 |
Why?
|
Pregnancy | 3 | 2013 | 2885 | 0.040 |
Why?
|
Overweight | 1 | 2019 | 118 | 0.040 |
Why?
|
Quality of Life | 2 | 2017 | 1575 | 0.040 |
Why?
|
Glycoproteins | 1 | 1999 | 234 | 0.040 |
Why?
|
17-alpha-Hydroxypregnenolone | 2 | 1994 | 12 | 0.040 |
Why?
|
Amino Acid Sequence | 1 | 2002 | 2062 | 0.040 |
Why?
|
Hepatocyte Nuclear Factor 1-beta | 1 | 2017 | 34 | 0.040 |
Why?
|
DNA Mutational Analysis | 1 | 1999 | 526 | 0.040 |
Why?
|
Preventive Health Services | 1 | 2018 | 37 | 0.040 |
Why?
|
Medication Adherence | 1 | 2019 | 129 | 0.040 |
Why?
|
Plasminogen Activator Inhibitor 1 | 1 | 1997 | 36 | 0.040 |
Why?
|
Glucokinase | 1 | 2017 | 61 | 0.040 |
Why?
|
Postprandial Period | 1 | 2017 | 47 | 0.040 |
Why?
|
Hepatocyte Nuclear Factor 1-alpha | 1 | 2017 | 80 | 0.040 |
Why?
|
Germany | 1 | 2017 | 72 | 0.040 |
Why?
|
Delayed-Action Preparations | 1 | 1997 | 116 | 0.040 |
Why?
|
Arginine | 1 | 2017 | 136 | 0.040 |
Why?
|
Chromosome Mapping | 2 | 1999 | 1074 | 0.040 |
Why?
|
Disease Models, Animal | 1 | 2003 | 2227 | 0.040 |
Why?
|
Calcinosis | 1 | 2018 | 224 | 0.040 |
Why?
|
Analysis of Variance | 1 | 1999 | 912 | 0.040 |
Why?
|
Infusions, Intravenous | 1 | 2017 | 429 | 0.040 |
Why?
|
Risk | 1 | 2018 | 673 | 0.040 |
Why?
|
Circadian Rhythm | 1 | 2019 | 303 | 0.040 |
Why?
|
Cost of Illness | 1 | 2017 | 150 | 0.040 |
Why?
|
DNA | 1 | 2002 | 1293 | 0.040 |
Why?
|
Drug Administration Schedule | 2 | 2010 | 916 | 0.030 |
Why?
|
B-Lymphocytes | 1 | 2001 | 724 | 0.030 |
Why?
|
Liver | 1 | 2021 | 1229 | 0.030 |
Why?
|
Asthma | 1 | 2003 | 947 | 0.030 |
Why?
|
Virilism | 1 | 1994 | 6 | 0.030 |
Why?
|
Adrenal Gland Diseases | 1 | 1994 | 13 | 0.030 |
Why?
|
Neurosecretory Systems | 1 | 1994 | 35 | 0.030 |
Why?
|
Adaptation, Psychological | 1 | 2015 | 157 | 0.030 |
Why?
|
Prevalence | 1 | 1999 | 1239 | 0.030 |
Why?
|
Trans-Activators | 1 | 2017 | 429 | 0.030 |
Why?
|
Dehydroepiandrosterone | 2 | 1993 | 51 | 0.030 |
Why?
|
Age of Onset | 1 | 2015 | 306 | 0.030 |
Why?
|
Self Care | 1 | 2015 | 164 | 0.030 |
Why?
|
Chicago | 1 | 1999 | 1377 | 0.030 |
Why?
|
Flutamide | 1 | 2013 | 4 | 0.030 |
Why?
|
Psychometrics | 1 | 2015 | 327 | 0.030 |
Why?
|
Pregnancy Trimester, Third | 1 | 2013 | 70 | 0.030 |
Why?
|
Homeodomain Proteins | 1 | 2017 | 535 | 0.030 |
Why?
|
Societies, Scientific | 1 | 2013 | 44 | 0.030 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 1680 | 0.030 |
Why?
|
Hypertension | 1 | 2002 | 1139 | 0.030 |
Why?
|
Clinical Trials as Topic | 2 | 2009 | 1168 | 0.030 |
Why?
|
Puberty | 1 | 1993 | 59 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2007 | 997 | 0.030 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2017 | 508 | 0.030 |
Why?
|
Double-Blind Method | 3 | 2003 | 1822 | 0.030 |
Why?
|
Guanine Nucleotide Exchange Factors | 1 | 2012 | 73 | 0.030 |
Why?
|
Treatment Outcome | 3 | 2017 | 7949 | 0.030 |
Why?
|
Pregnancy Trimester, Second | 1 | 2011 | 66 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2012 | 399 | 0.030 |
Why?
|
Quantitative Trait Loci | 1 | 2015 | 576 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2012 | 321 | 0.020 |
Why?
|
Venous Thromboembolism | 1 | 2013 | 151 | 0.020 |
Why?
|
Pituitary Hormone-Releasing Hormones | 1 | 1990 | 9 | 0.020 |
Why?
|
Dosage Forms | 1 | 2010 | 7 | 0.020 |
Why?
|
United States | 2 | 2015 | 6637 | 0.020 |
Why?
|
Periodicity | 1 | 2010 | 119 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 2 | 2018 | 2594 | 0.020 |
Why?
|
Theca Cells | 1 | 2009 | 12 | 0.020 |
Why?
|
Anovulation | 1 | 2009 | 10 | 0.020 |
Why?
|
Stimulation, Chemical | 1 | 1989 | 63 | 0.020 |
Why?
|
Inhibins | 1 | 2009 | 37 | 0.020 |
Why?
|
Occupations | 1 | 2009 | 26 | 0.020 |
Why?
|
Granulosa Cells | 1 | 2009 | 28 | 0.020 |
Why?
|
Chorionic Gonadotropin | 1 | 2009 | 71 | 0.020 |
Why?
|
19-Iodocholesterol | 1 | 1988 | 1 | 0.020 |
Why?
|
Gonadal Steroid Hormones | 1 | 2009 | 50 | 0.020 |
Why?
|
Adrenal Cortex Diseases | 1 | 1988 | 6 | 0.020 |
Why?
|
Adrenal Cortex | 1 | 1988 | 21 | 0.020 |
Why?
|
Cushing Syndrome | 1 | 1988 | 24 | 0.020 |
Why?
|
Ovarian Follicle | 1 | 2009 | 69 | 0.020 |
Why?
|
Immunoassay | 1 | 1989 | 92 | 0.020 |
Why?
|
Pelvis | 1 | 2009 | 94 | 0.020 |
Why?
|
Hyperthyroidism | 1 | 1989 | 75 | 0.020 |
Why?
|
Research Support as Topic | 1 | 2009 | 80 | 0.020 |
Why?
|
Iodine Radioisotopes | 1 | 1988 | 134 | 0.020 |
Why?
|
Nuclear Family | 2 | 1999 | 92 | 0.020 |
Why?
|
Estrogens | 1 | 1989 | 197 | 0.020 |
Why?
|
Risk Assessment | 1 | 2015 | 2253 | 0.020 |
Why?
|
Logistic Models | 1 | 2011 | 1184 | 0.020 |
Why?
|
Hypothyroidism | 1 | 1989 | 232 | 0.020 |
Why?
|
Pilot Projects | 1 | 1989 | 837 | 0.020 |
Why?
|
Placebos | 1 | 2007 | 218 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2015 | 1917 | 0.020 |
Why?
|
Body Size | 1 | 2007 | 91 | 0.020 |
Why?
|
Cholesterol | 1 | 1988 | 356 | 0.020 |
Why?
|
Thyroid Hormones | 1 | 1989 | 318 | 0.020 |
Why?
|
Electrophoretic Mobility Shift Assay | 1 | 2005 | 72 | 0.020 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 2005 | 147 | 0.020 |
Why?
|
Luciferases | 1 | 2005 | 118 | 0.020 |
Why?
|
Genes, Reporter | 1 | 2005 | 266 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2007 | 857 | 0.020 |
Why?
|
Biomedical Research | 1 | 2009 | 375 | 0.020 |
Why?
|
Bronchial Provocation Tests | 1 | 2003 | 24 | 0.020 |
Why?
|
Hypersensitivity, Delayed | 1 | 2003 | 25 | 0.020 |
Why?
|
Aerosols | 1 | 2003 | 44 | 0.020 |
Why?
|
Macaca fascicularis | 1 | 2003 | 108 | 0.020 |
Why?
|
Respiratory Hypersensitivity | 1 | 2003 | 41 | 0.010 |
Why?
|
Transfection | 1 | 2005 | 895 | 0.010 |
Why?
|
Histamine | 1 | 2003 | 126 | 0.010 |
Why?
|
Hypersensitivity, Immediate | 1 | 2003 | 62 | 0.010 |
Why?
|
Electroencephalography | 1 | 2008 | 707 | 0.010 |
Why?
|
Respiratory Function Tests | 1 | 2003 | 136 | 0.010 |
Why?
|
Immunization | 1 | 2003 | 158 | 0.010 |
Why?
|
Immunoglobulin E | 1 | 2003 | 143 | 0.010 |
Why?
|
Respiratory System | 1 | 2003 | 116 | 0.010 |
Why?
|
Triglycerides | 1 | 2003 | 232 | 0.010 |
Why?
|
Th2 Cells | 1 | 2003 | 146 | 0.010 |
Why?
|
Cholesterol, LDL | 1 | 2003 | 222 | 0.010 |
Why?
|
Prognosis | 1 | 2010 | 3669 | 0.010 |
Why?
|
Child, Preschool | 1 | 2009 | 3608 | 0.010 |
Why?
|
Signal Transduction | 1 | 2012 | 3233 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2003 | 456 | 0.010 |
Why?
|
Adenosine | 1 | 2003 | 224 | 0.010 |
Why?
|
Fatty Acids, Nonesterified | 1 | 2000 | 70 | 0.010 |
Why?
|
Kinetics | 2 | 1993 | 1513 | 0.010 |
Why?
|
Puberty, Precocious | 1 | 2000 | 36 | 0.010 |
Why?
|
Cytokines | 1 | 2003 | 775 | 0.010 |
Why?
|
Minisatellite Repeats | 1 | 1999 | 24 | 0.010 |
Why?
|
Follistatin | 1 | 1999 | 7 | 0.010 |
Why?
|
Open Reading Frames | 1 | 1999 | 117 | 0.010 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 1999 | 79 | 0.010 |
Why?
|
Fathers | 1 | 1999 | 68 | 0.010 |
Why?
|
Retrospective Studies | 2 | 1989 | 8431 | 0.010 |
Why?
|
Genetic Markers | 1 | 1999 | 476 | 0.010 |
Why?
|
Mothers | 1 | 1999 | 140 | 0.010 |
Why?
|
Exons | 1 | 1999 | 450 | 0.010 |
Why?
|
Guinea Pigs | 1 | 1997 | 171 | 0.010 |
Why?
|
Lung | 1 | 2003 | 1167 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 1999 | 927 | 0.010 |
Why?
|
Information Systems | 1 | 1996 | 29 | 0.010 |
Why?
|
Japan | 1 | 1996 | 307 | 0.010 |
Why?
|
Gene Expression | 1 | 2000 | 1281 | 0.010 |
Why?
|
Hydrolases | 1 | 1994 | 28 | 0.010 |
Why?
|
Family | 1 | 1996 | 311 | 0.010 |
Why?
|
Pedigree | 1 | 1996 | 966 | 0.010 |
Why?
|
Adrenal Gland Neoplasms | 1 | 1994 | 80 | 0.010 |
Why?
|
Models, Genetic | 1 | 1999 | 926 | 0.010 |
Why?
|
Adrenal Cortex Neoplasms | 1 | 1988 | 18 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1988 | 274 | 0.010 |
Why?
|
Hyperplasia | 1 | 1988 | 148 | 0.010 |
Why?
|
Radionuclide Imaging | 1 | 1988 | 220 | 0.010 |
Why?
|
Aging | 1 | 1993 | 689 | 0.010 |
Why?
|
Mice | 1 | 2000 | 11313 | 0.000 |
Why?
|
Adenoma | 1 | 1988 | 234 | 0.000 |
Why?
|
Carcinoma | 1 | 1988 | 434 | 0.000 |
Why?
|